Coherus BioSciences Inc (CHRS)

15.80
NASDAQ : Health Care
Prev Close 15.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 14.00 / 31.98
Avg Volume 738.90K
Exchange NASDAQ
Shares Outstanding 51.29M
Market Cap 792.40M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: Coherus, XBiotech, Flexion

Biotech Movers: Coherus, XBiotech, Flexion

Coherus BioSciences, XBiotech and Flexion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Coherus BioSciences Receives Complete Response Letter From FDA For Its Biologics License Application For CHS-1701 (Pegfilgrastim Biosimilar Candidate)

Management to host a call today at 8:00 a.m. EDT to discuss FDA feedback

First Week of CHRS July 21st Options Trading

Investors in Coherus BioSciences Inc saw new options become available this week, for the July 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CHRS options chain for the new July 21st contracts and identified one put and one call contract of particular interest.

AbbVie Stock Lower on Humira Patent Ruling

AbbVie Stock Lower on Humira Patent Ruling

The drug is responsible for more than 60% of AbbVie's top line.

Coherus BioSciences Prevails In '135 IPR Decision

Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135

First Week of June 16th Options Trading For Coherus BioSciences (CHRS)

Investors in Coherus BioSciences Inc saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CHRS options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Oversold Conditions For Coherus BioSciences (CHRS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Here's What Blackstone Bought and Sold in the Fourth Quarter

Here's What Blackstone Bought and Sold in the Fourth Quarter

Private equity firms' publicly traded equity holdings are a valuable source of ideas for growth and value investors, alike.

Here's What Blackstone and KKR Are Buying

Here's What Blackstone and KKR Are Buying

Private equity firms' publicly traded equity holdings are a valuable source of ideas for growth and value investors, alike.